Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

BACKGROUND: Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/i...

Descripción completa

Detalles Bibliográficos
Autores principales: Giagounidis, Aristoteles, Mufti, Ghulam J, Fenaux, Pierre, Sekeres, Mikkael A, Szer, Jeffrey, Platzbecker, Uwe, Kuendgen, Andrea, Gaidano, Gianluca, Wiktor-Jedrzejczak, Wieslaw, Hu, Kuolung, Woodard, Paul, Yang, Allen S, Kantarjian, Hagop M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298760/
https://www.ncbi.nlm.nih.gov/pubmed/24706489
http://dx.doi.org/10.1002/cncr.28663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298760/
https://www.ncbi.nlm.nih.gov/pubmed/24706489
http://dx.doi.org/10.1002/cncr.28663

Ejemplares similares